CompanyIMANasdaqSan Diego, CA

ImageneBio, Inc.

Imagene develops olevaprubart, a nondepleting anti-OX40 monoclonal antibody for immunological, autoimmune, and inflammatory diseases.

SEC EDGAR ClinicalTrials.gov imagenebio.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 5Latest story

August 2026

ImageneBio reports Q2 2026 results as olevaprubart pipeline advances on schedule

Aug 5Quarterly updateImageneBio, Inc.

July 2026

ImageneBio names Yanina Grant-Huerta as CFO, effective July 20, 2026

Jul 23PeopleImageneBio, Inc.